CG Oncology (CGON) News Today $32.24 -0.56 (-1.71%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual MeetingNovember 20 at 10:38 AM | markets.businessinsider.comFY2024 EPS Estimates for CG Oncology Increased by AnalystNovember 19 at 2:29 AM | americanbankingnews.comShort Interest in CG Oncology, Inc. (NASDAQ:CGON) Drops By 6.0%CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 5,600,000 shares, a decrease of 6.0% from the October 15th total of 5,960,000 shares. Currently, 13.9% of the company's shares are short sold. Based on an average daily volume of 638,000 shares, the short-interest ratio is currently 8.8 days.November 18 at 8:46 AM | marketbeat.comCG Oncology FY2024 EPS Estimate Lifted by Cantor FitzgeraldCG Oncology, Inc. (NASDAQ:CGON - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for shares of CG Oncology in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company wilNovember 18 at 2:30 AM | marketbeat.comLos Angeles Capital Management LLC Takes Position in CG Oncology, Inc. (NASDAQ:CGON)Los Angeles Capital Management LLC purchased a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,052 shares oNovember 16, 2024 | marketbeat.comFY2024 EPS Estimates for CG Oncology Lifted by HC WainwrightCG Oncology, Inc. (NASDAQ:CGON - Free Report) - Analysts at HC Wainwright increased their FY2024 EPS estimates for CG Oncology in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($1.33) per sharNovember 15, 2024 | marketbeat.comCG Oncology FY2024 EPS Forecast Increased by Lifesci CapitalCG Oncology, Inc. (NASDAQ:CGON - Free Report) - Research analysts at Lifesci Capital upped their FY2024 earnings estimates for CG Oncology in a report issued on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($1.41) per share for theNovember 15, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Earns "Buy" Rating from HC WainwrightNovember 14, 2024 | americanbankingnews.comCG Oncology’s Financial Results and Clinical DevelopmentsNovember 14, 2024 | tipranks.comCG Oncology (NASDAQ:CGON) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPSCG Oncology (NASDAQ:CGON - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.30 million.November 13, 2024 | marketbeat.comAnalysts Set CG Oncology, Inc. (NASDAQ:CGON) Price Target at $63.88November 13, 2024 | americanbankingnews.comPromising Prospects for CG Oncology, Inc.: Buy Rating Reinforced by Positive MIBC Treatment Outcomes and Market OpportunitiesNovember 12, 2024 | markets.businessinsider.comCG Oncology Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 12, 2024 | markets.businessinsider.comCG Oncology (NASDAQ:CGON) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of CG Oncology in a report on Tuesday.November 12, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Position Increased by TimesSquare Capital Management LLCTimesSquare Capital Management LLC increased its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 27.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 437,069 shares of the company's stock after buying an additional 94,010 shares duriNovember 11, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of "Buy" from AnalystsShares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine ratings firms that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one haNovember 10, 2024 | marketbeat.comDiscover the 3 Best-Performing Biotech IPO Stocks of 2024 (CGON)Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.November 6, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 14.5% in OctoberCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 5,960,000 shares, a drop of 14.5% from the September 30th total of 6,970,000 shares. Based on an average trading volume of 703,100 shares, the short-interest ratio is currently 8.5 days. Approximately 14.8% of the shares of the company are short sold.October 29, 2024 | marketbeat.comCG Oncology initiated with a Buy at UBSOctober 25, 2024 | markets.businessinsider.comUBS Initiates Coverage of CG Oncology (CGON) with Buy RecommendationOctober 25, 2024 | msn.comCG Oncology (NASDAQ:CGON) Coverage Initiated by Analysts at UBS GroupUBS Group started coverage on shares of CG Oncology in a research report on Thursday. They set a "buy" rating and a $60.00 target price on the stock.October 24, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Rating of "Buy" from AnalystsCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) has been given a consensus recommendation of "Buy" by the eight analysts that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the coOctober 16, 2024 | marketbeat.comSG Americas Securities LLC Invests $664,000 in CG Oncology, Inc. (NASDAQ:CGON)SG Americas Securities LLC acquired a new position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,595 shares of the company's stock, valued at approximaOctober 14, 2024 | marketbeat.comOptimistic Outlook for CG Oncology as Trial Cessation Boosts Cretostimogene ProspectsOctober 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology Amidst Bladder Cancer Market OpportunitiesOctober 8, 2024 | markets.businessinsider.comBank of America Reaffirms "Buy" Rating for CG Oncology (NASDAQ:CGON)Bank of America reaffirmed a "buy" rating and set a $65.00 price target on shares of CG Oncology in a research note on Tuesday.October 8, 2024 | marketbeat.comRenaissance Technologies LLC Purchases 29,000 Shares of CG Oncology, Inc. (NASDAQ:CGON)Renaissance Technologies LLC lifted its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 204.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,200 shares of the company's stock after pOctober 5, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Stock, Short Interest ReportOctober 4, 2024 | benzinga.com75,982 Shares in CG Oncology, Inc. (NASDAQ:CGON) Bought by Marshall Wace LLPMarshall Wace LLP bought a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 75,982 shares of the company's stock, valued at approximately $2,399,000. MarOctober 4, 2024 | marketbeat.comPoint72 Asset Management L.P. Sells 75,827 Shares of CG Oncology, Inc. (NASDAQ:CGON)Point72 Asset Management L.P. lessened its position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 40.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,410 shares of theOctober 3, 2024 | marketbeat.comWe Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business GrowthOctober 1, 2024 | finance.yahoo.comCG Oncology, Inc. (NASDAQ:CGON) Shares Sold by Perceptive Advisors LLCPerceptive Advisors LLC lowered its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 43.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 733,695 shares of the company's stock after sellingSeptember 30, 2024 | marketbeat.comEnsign Peak Advisors Inc Takes $1.91 Million Position in CG Oncology, Inc. (NASDAQ:CGON)Ensign Peak Advisors Inc acquired a new position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 60,565 shares of the company's stock, valued at approximately $1,912,000. EnsignSeptember 28, 2024 | marketbeat.comBuy Rating Affirmed for CG Oncology Amid Strong Clinical Performance and Promising Market ProspectsSeptember 27, 2024 | markets.businessinsider.comDeerfield Management Company L.P. Series C Increases Stake in CG Oncology, Inc. (NASDAQ:CGON)Deerfield Management Company L.P. Series C grew its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 811.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 433,540 shares of tSeptember 26, 2024 | marketbeat.comRBC Capital Initiates Coverage of CG Oncology (CGON) with Outperform RecommendationSeptember 24, 2024 | msn.comRoyal Bank of Canada Initiates Coverage on CG Oncology (NASDAQ:CGON)Royal Bank of Canada started coverage on CG Oncology in a report on Monday. They set an "outperform" rating and a $66.00 target price for the company.September 23, 2024 | marketbeat.comYu Fan Takes $49.83 Million Position in CG Oncology, Inc. (NASDAQ:CGON)Yu Fan purchased a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,578,344 shares of the company's stock, valued at approximately $49,828,000. CG Oncology accountsSeptember 23, 2024 | marketbeat.comImmunityBio: Anktiva Launch, Good Data, Low Cash, High DebtSeptember 21, 2024 | seekingalpha.comCG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 11.2% in AugustCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) saw a significant decline in short interest in August. As of August 31st, there was short interest totalling 6,200,000 shares, a decline of 11.2% from the August 15th total of 6,980,000 shares. Based on an average daily trading volume, of 563,500 shares, the short-interest ratio is currently 11.0 days. Currently, 15.4% of the shares of the company are short sold.September 17, 2024 | marketbeat.comMaintaining Buy Rating on CG Oncology Amid Competitive Edge and Positive Trial OutcomesSeptember 17, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for CG Oncology (NASDAQ:CGON)HC Wainwright restated a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a research note on Tuesday.September 17, 2024 | marketbeat.comCGON Sep 2024 45.000 callSeptember 17, 2024 | nz.finance.yahoo.comBuy Rating Affirmed for CG Oncology Amid Competitive Landscape and Strong Clinical ResultsSeptember 16, 2024 | markets.businessinsider.comCG Oncology surges 7%; seen benefitting from J&J bladder cancer asset dataSeptember 16, 2024 | msn.comCG Oncology (NASDAQ:CGON) Stock Price Up 4.6%CG Oncology (NASDAQ:CGON) Stock Price Up 4.6%September 16, 2024 | marketbeat.comBank of New York Mellon Corp Has $2.82 Million Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON)Bank of New York Mellon Corp boosted its stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 38.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 89,344 shares of the company's stock after purchasing an additionaSeptember 16, 2024 | marketbeat.comCg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer StockSeptember 14, 2024 | msn.com10 Worst Cancer Stocks To Buy Now According to Short SellersSeptember 13, 2024 | insidermonkey.comTD Asset Management Inc Invests $2.94 Million in CG Oncology, Inc. (NASDAQ:CGON)TD Asset Management Inc purchased a new stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 93,084 shares of the company's stock, valued at approximately $2,939,000. TD AssetSeptember 13, 2024 | marketbeat.com Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide CGON Media Mentions By Week CGON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGON News Sentiment▼1.030.46▲Average Medical News Sentiment CGON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGON Articles This Week▼183▲CGON Articles Average Week Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Today Ascendis Pharma A/S News Today Legend Biotech News Today Elanco Animal Health News Today Cytokinetics News Today Blueprint Medicines News Today Nuvalent News Today Viking Therapeutics News Today Lantheus News Today Avidity Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGON) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
